Reveal Biosciences is creating a new generation of data powered pathology to enhance research and improve healthcare. AI technologies have now advanced such that they can be used for whole slide pathology to reveal whether a patient has a disease. Reveal is using this technology to create a new generation of Pathology Intelligence services: [1] high quality histopathology research services, [2] access to the most advanced AI-powered cloud digital assay platform for image diagnostics and [3] AI-powered clinical decision support tools to improve patient outcomes. Reveal’s pipeline of AI-based digital assays can be applied to preclinical research, clinical trials and diagnostics and can enhance pathology workflows.

<p>Reveal Biosciences is creating a new generation of data powered pathology to enhance research and improve healthcare. AI technologies have now advanced such that they can be used for whole slide pathology to reveal whether a patient has a disease. Reveal is using this technology to create a new generation of Pathology Intelligence services: [1] high quality histopathology research services, [2] access to the most advanced AI-powered cloud digital assay platform for image diagnostics and [3] AI-powered clinical decision support tools to improve patient outcomes. Reveal’s pipeline of AI-based digital assays can be applied to preclinical research, clinical trials and diagnostics and can enhance pathology workflows.</p>


Reveal Biosciences

Briana I. Martinez - Morrison Foerster

 Intel Capital invests $117 mln into 14 companies 

Global Digital Pathology Image Analysis Software Market Size, - openPR

Pathologie numérique et analyse d’images

Artificial Intelligence-powered (AI) Spatial Biology Market Size, Share, Growth Analysis Report to 2 - InsightAce Analytic

 Reveal Biosciences Gets Intel’s Backing on “AI-Powered” Pathology 

CellCarta Strengthens its Histological Biomarker Franchise by Acquiring Artificial Intelligence-Based Quantitative Pathology Leader Reveal Biosciences - PR Newswire

Following its acquisition in 2021, Reveal Biosciences’ technologies and operations are now an integral part of CellCarta’s offering. This account will close at the end of the month.

To stay in touch with all things digital pathology and AI offered at CellCarta, please follow our on main account!

 Venture Capital Database 2019 Now Available! 

Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer | npj Breast Cancer - Nature.com

Linking violence in Myanmar to fossil amber research, and waking up bacterial spores - Science

How dormant bacteria spores sense when it’s time to come back to life - Science News Magazine

Reveal Biosciences, a Global Pathology AI Leader, Raises Series A Funding Led by Intel Capital - Business Wire

Reveal Biosciences

Business:

About: